KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer
Status:
Recruiting
Trial end date:
2022-02-25
Target enrollment:
Participant gender:
Summary
This is a two-part (dose-escalation, dose-expansion), multicenter, open-label Phase 1 study
of KHK2455 in combination with avelumab in adult subjects with locally advanced or metastatic
urothelial carcinoma (including bladder, urethra, ureters, and renal pelvis).
Phase:
Phase 1
Details
Lead Sponsor:
Kyowa Kirin Pharmaceutical Development, Inc. Kyowa Kirin, Inc.